{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T02:26:46Z","timestamp":1769480806299,"version":"3.49.0"},"posted":{"date-parts":[[2025,8,11]]},"group-title":"In Review","reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,5,12]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background:<\/bold>\n                  Histone deacetylases (HDACs) are epigenetic molecules responsible for regulation of gene transcription. Altered expression of HDACs has been linked to neurodegenerative disease. Here, we used the class I HDAC PET radioligand [\n                  <sup>11<\/sup>\n                  C]Martinostat to quantify and map changes in these molecules in the brain in dementia with Lewy bodies (DLB) and Parkinson\u2019s disease (PD). In this cross-sectional study, we acquired brain PET-MR with [\n                  <sup>11<\/sup>\n                  C]Martinostat in 14 DLB (median age 70 years (IQR 14), 21% female), 10 PD (median age 70 (8), 20% female) including four with cognitive impairment and six without, and 17 healthy control (HC) participants (median age 62 (14), 47% female). [\n                  <sup>11<\/sup>\n                  C]Martinostat uptake was compared amongst groups using  whole brain voxel-wise analysis and targeted region of interest (ROI)-based approaches, adjusted for age and sex. Regional  expression was also quantified in postmortem brain bank samples.\n                  <bold>Results:<\/bold>\n                  Compared to HC, [\n                  <sup>11<\/sup>\n                  C]Martinostat uptake in DLB was increased in precentral gyrus (ROI\n                  <italic>p<\/italic>\n                  = 0.044) and putamen (\n                  <italic>p<\/italic>\n                  &lt; 0.001) , as well as in cognitive and limbic circuitry including anterior cingulate (\n                  <italic>p<\/italic>\n                  = 0.042) and entorhinal cortex (\n                  <italic>p<\/italic>\n                  = 0.023). [\n                  <sup>11<\/sup>\n                  C]Martinostat uptake in DLB was decreased in inferior parietal cortex\n                  <italic>p<\/italic>\n                  &lt; 0.001) compared to HC, consistent with prior observations in Alzheimer\u2019s disease. In PD, [\n                  <sup>11<\/sup>\n                  C]Martinostat uptake was also increased in precentral gyrus (\n                  <italic>p<\/italic>\n                  = 0.019 in those with normal cognition,\n                  <italic>p<\/italic>\n                  = 0.047 in those with impaired cognition), correlating with both disease duration\n                  <italic\/>\n                  and stage. In cognitively impaired PD, [\n                  <sup>11<\/sup>\n                  C]Martinostat uptake was additionally reduced in inferior parietal cortex (\n                  <italic>p<\/italic>\n                  = 0.011), similar to DLB. In postmortem DLB tissue, class I HDAC expression was elevated in anterior cingulate cortex (isoform 1\n                  <italic>p<\/italic>\n                  = 0.041, isoform 3\n                  <italic>p<\/italic>\n                  = 0.024) and reduced in inferior parietal cortex (isoform 1\n                  <italic>p<\/italic>\n                  &lt; 0.001).\n                  <bold>Conclusions:<\/bold>\n                  These findings reveal evidence of elevated class I HDACs in motor cortex in PD and bidirectional changes in their regional expression in the Lewy body dementias.\n                <\/p>","DOI":"10.21203\/rs.3.rs-6647341\/v1","type":"posted-content","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T07:14:20Z","timestamp":1754896460000},"source":"Crossref","is-referenced-by-count":0,"title":["Imaging brain class I histone deacetylase changes in the Lewy body dementias and Parkinson\u2019s disease"],"prefix":"10.21203","author":[{"given":"Anna","family":"Goodheart","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Hyeon","family":"Yoo","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Fassini","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tewodros","family":"Dagnew","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Ye","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Striar","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moqing","family":"Quan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rattray","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Meyer","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Peterec","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Lee","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Fiedler","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Hooker","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao-Ying","family":"Wey","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changning","family":"Wang","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Gomperts","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrn.2017.46","article-title":"The emerging field of epigenetics in neurodegeneration and neuroprotection","volume":"18","author":"Hwang JY","year":"2017","unstructured":"Hwang JY, Aromolaran KA, Zukin RS. The emerging field of epigenetics in neurodegeneration and neuroprotection. Nat Rev Neurosci. 2017;18(6):347\u201361.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.vascn.2012.08.001","article-title":"Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders","volume":"66","author":"Konsoula Z","year":"2012","unstructured":"Konsoula Z, Barile FA. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. J Pharmacol Toxicol Methods. 2012;66(3):215\u201320.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nn.3302","article-title":"Epigenetics and persistent memory: implications for reconsolidation and silent extinction beyond the zero","volume":"16","author":"Lattal KM","year":"2013","unstructured":"Lattal KM, Wood MA. Epigenetics and persistent memory: implications for reconsolidation and silent extinction beyond the zero. Nat Neurosci. 2013;16(2):124\u20139.","journal-title":"Nat Neurosci"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1523\/JNEUROSCI.5052-10.2011","article-title":"HDAC3 is a critical negative regulator of long-term memory formation","volume":"31","author":"McQuown SC","year":"2011","unstructured":"McQuown SC, Barrett RM, Matheos DP, Post RJ, Rogge GA, Alenghat T, et al. HDAC3 is a critical negative regulator of long-term memory formation. J Neurosci. 2011;31(2):764\u201374.","journal-title":"J Neurosci"},{"issue":"5979","key":"ref5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1126\/science.1186088","article-title":"Altered histone acetylation is associated with age-dependent memory impairment in mice","volume":"328","author":"Peleg S","year":"2010","unstructured":"Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, Agis-Balboa RC, et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science. 2010;328(5979):753\u20136.","journal-title":"Science"},{"issue":"355","key":"ref6","doi-asserted-by":"crossref","first-page":"re12","DOI":"10.1126\/scisignal.aaa0069","article-title":"Histone deacetylases in memory and cognition","volume":"7","author":"Penney J","year":"2014","unstructured":"Penney J, Tsai LH. Histone deacetylases in memory and cognition. Sci Signal. 2014;7(355):re12.","journal-title":"Sci Signal"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.it.2011.04.001","article-title":"Histone deacetylases as regulators of inflammation and immunity","volume":"32","author":"Shakespear MR","year":"2011","unstructured":"Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 2011;32(7):335\u201343.","journal-title":"Trends Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3389\/fphar.2020.00537","article-title":"Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation","volume":"11","author":"Shukla S","year":"2020","unstructured":"Shukla S, Tekwani BL. Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation. Front Pharmacol. 2020;11:537.","journal-title":"Front Pharmacol"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/acel.12642","article-title":"HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease","volume":"16","author":"Zhu X","year":"2017","unstructured":"Zhu X, Wang S, Yu L, Jin J, Ye X, Liu Y, et al. HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease. Aging Cell. 2017;16(5):1073\u201382.","journal-title":"Aging Cell"},{"issue":"7243","key":"ref10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature07925","article-title":"HDAC2 negatively regulates memory formation and synaptic plasticity","volume":"459","author":"Guan JS","year":"2009","unstructured":"Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459(7243):55\u201360.","journal-title":"Nature"},{"issue":"16","key":"ref11","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1111\/bph.13208","article-title":"Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors","volume":"172","author":"Harrison IF","year":"2015","unstructured":"Harrison IF, Crum WR, Vernon AC, Dexter DT. Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors. Br J Pharmacol. 2015;172(16):4200\u201315.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2013.05.010","article-title":"Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?","volume":"140","author":"Harrison IF","year":"2013","unstructured":"Harrison IF, Dexter DT. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? Pharmacol Ther. 2013;140(1):34\u201352.","journal-title":"Pharmacol Ther"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4103\/1673-5374.194803","article-title":"The Epigenome as a therapeutic target for Parkinson's disease","volume":"11","author":"Hegarty SV","year":"2016","unstructured":"Hegarty SV, Sullivan AM, O'Keeffe GW. The Epigenome as a therapeutic target for Parkinson's disease. Neural Regen Res. 2016;11(11):1735\u20138.","journal-title":"Neural Regen Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neuroscience.2011.08.010","article-title":"Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"194","author":"Kidd SK","year":"2011","unstructured":"Kidd SK, Schneider JS. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience. 2011;194:189\u201394.","journal-title":"Neuroscience"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/npp.2009.197","article-title":"Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease","volume":"35","author":"Kilgore M","year":"2010","unstructured":"Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 2010;35(4):870\u201380.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5607\/en.2019.28.4.504","article-title":"HDAC Inhibition by Valproic Acid Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G Transgenic Mice","volume":"28","author":"Kim T","year":"2019","unstructured":"Kim T, Song S, Park Y, Kang S, Seo H. HDAC Inhibition by Valproic Acid Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G Transgenic Mice. Exp Neurobiol. 2019;28(4):504\u201315.","journal-title":"Exp Neurobiol"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00401-016-1590-9","article-title":"Epigenetic regulation in Parkinson's disease","volume":"132","author":"Labbe C","year":"2016","unstructured":"Labbe C, Lorenzo-Betancor O, Ross OA. Epigenetic regulation in Parkinson's disease. Acta Neuropathol. 2016;132(4):515\u201330.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12640-009-9090-5","article-title":"Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein","volume":"17","author":"Monti B","year":"2010","unstructured":"Monti B, Gatta V, Piretti F, Raffaelli SS, Virgili M, Contestabile A. Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res. 2010;17(2):130\u201341.","journal-title":"Neurotox Res"},{"issue":"5837","key":"ref19","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.1143780","article-title":"Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease","volume":"317","author":"Outeiro TF","year":"2007","unstructured":"Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science. 2007;317(5837):516\u20139.","journal-title":"Science"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.molbrainres.2004.10.021","article-title":"Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia","volume":"134","author":"Peng GS","year":"2005","unstructured":"Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, et al. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol Brain Res. 2005;134(1):162\u20139.","journal-title":"Brain Res Mol Brain Res"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s42003-023-05725-x","article-title":"Differential methylation analysis in neuropathologically confirmed dementia with Lewy bodies","volume":"7","author":"Reho P","year":"2024","unstructured":"Reho P, Saez-Atienzar S, Ruffo P, Solaiman S, Shah Z, Chia R, et al. Differential methylation analysis in neuropathologically confirmed dementia with Lewy bodies. Commun Biol. 2024;7(1):35.","journal-title":"Commun Biol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neurobiolaging.2018.02.018","article-title":"Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease","volume":"68","author":"Tan Y","year":"2018","unstructured":"Tan Y, Delvaux E, Nolz J, Coleman PD, Chen S, Mastroeni D. Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease. Neurobiol Aging. 2018;68:134\u201341.","journal-title":"Neurobiol Aging"},{"key":"ref23","first-page":"313702","article-title":"Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties","volume":"2015","author":"Ximenes JC","year":"2015","unstructured":"Ximenes JC, Neves KR, Leal LK, do Carmo MR, Brito GA, Naffah-Mazzacoratti Mda G, et al. Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties. J Neurodegener Dis. 2015;2015:313702.","journal-title":"J Neurodegener Dis"},{"key":"ref24","first-page":"143269","article-title":"Targeting HDACs: a promising therapy for Alzheimer's disease","volume":"2011","author":"Xu K","year":"2011","unstructured":"Xu K, Dai XL, Huang HC, Jiang ZF. Targeting HDACs: a promising therapy for Alzheimer's disease. Oxid Med Cell Longev. 2011;2011:143269.","journal-title":"Oxid Med Cell Longev"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbadis.2018.11.014","article-title":"Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer's and Parkinson disease pathology","volume":"1865","author":"Esteves AR","year":"2019","unstructured":"Esteves AR, Palma AM, Gomes R, Santos D, Silva DF, Cardoso SM. Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer's and Parkinson disease pathology. Biochim Biophys Acta Mol Basis Dis. 2019;1865(8):2008\u201323.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neulet.2017.12.037","article-title":"Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition","volume":"666","author":"Harrison IF","year":"2018","unstructured":"Harrison IF, Smith AD, Dexter DT. Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition. Neurosci Lett. 2018;666:48\u201357.","journal-title":"Neurosci Lett"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/cns.12217","article-title":"Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+","volume":"20","author":"Zhu M","year":"2014","unstructured":"Zhu M, Li WW, Lu CZ. Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+. CNS Neurosci Ther. 2014;20(4):308\u201316.","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13024-021-00450-7","article-title":"Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson's disease brain","volume":"16","author":"Toker L","year":"2021","unstructured":"Toker L, Tran GT, Sundaresan J, Tysnes OB, Alves G, Haugarvoll K, et al. Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson's disease brain. Mol Neurodegener. 2021;16(1):31.","journal-title":"Mol Neurodegener"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neulet.2016.05.060","article-title":"Histone H3 acetylation in the postmortem Parkinson's disease primary motor cortex","volume":"627","author":"Gebremedhin KG","year":"2016","unstructured":"Gebremedhin KG, Rademacher DJ. Histone H3 acetylation in the postmortem Parkinson's disease primary motor cortex. Neurosci Lett. 2016;627:121\u20135.","journal-title":"Neurosci Lett"},{"issue":"20","key":"ref30","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/hmg\/ddl243","article-title":"Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity","volume":"15","author":"Kontopoulos E","year":"2006","unstructured":"Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet. 2006;15(20):3012\u201323.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/089198870201500406","article-title":"Dementia with Lewy bodies: neuropathology","volume":"15","author":"Dickson DW","year":"2002","unstructured":"Dickson DW. Dementia with Lewy bodies: neuropathology. J Geriatr Psychiatry Neurol. 2002;15(4):210\u20136.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","DOI":"10.4172\/2161-0460.1000444","article-title":"The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders","volume":"8","author":"Irwin DJ","year":"2018","unstructured":"Irwin DJ, Hurtig HI. The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. J Alzheimers Dis Parkinsonism. 2018;8(4).","journal-title":"J Alzheimers Dis Parkinsonism"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1212\/01.wnl.0000326146.60732.d6","article-title":"Imaging amyloid deposition in Lewy body diseases","volume":"71","author":"Gomperts SN","year":"2008","unstructured":"Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71(12):903\u201310.","journal-title":"Neurology"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak H","year":"2003","unstructured":"Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197\u2013211.","journal-title":"Neurobiol Aging"},{"issue":"2 Dementia","key":"ref35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/CON.0000000000000309","article-title":"Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia","volume":"22","author":"Gomperts SN","year":"2016","unstructured":"Gomperts SN. Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia. Continuum (Minneap Minn). 2016;22(2 Dementia):435\u201363.","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s004010100390","article-title":"Cortical Lewy body pathology in the diagnosis of dementia","volume":"102","author":"Harding AJ","year":"2001","unstructured":"Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001;102(4):355\u201363.","journal-title":"Acta Neuropathol"},{"issue":"19","key":"ref37","doi-asserted-by":"crossref","first-page":"7999","DOI":"10.1021\/jm500872p","article-title":"In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs","volume":"57","author":"Wang C","year":"2014","unstructured":"Wang C, Schroeder FA, Wey HY, Borra R, Wagner FF, Reis S, et al. In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs. J Med Chem. 2014;57(19):7999\u20138009.","journal-title":"J Med Chem"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/acschemneuro.5b00066","article-title":"Kinetic Analysis and Quantification of [(1)(1)C]Martinostat for in Vivo HDAC Imaging of the Brain","volume":"6","author":"Wey HY","year":"2015","unstructured":"Wey HY, Wang C, Schroeder FA, Logan J, Price JC, Hooker JM. Kinetic Analysis and Quantification of [(1)(1)C]Martinostat for in Vivo HDAC Imaging of the Brain. ACS Chem Neurosci. 2015;6(5):708\u201315.","journal-title":"ACS Chem Neurosci"},{"issue":"351","key":"ref39","first-page":"351ra106","article-title":"Insights into neuroepigenetics through human histone deacetylase PET imaging","volume":"8","author":"Wey HY","year":"2016","unstructured":"Wey HY, Gilbert TM, Zurcher NR, She A, Bhanot A, Taillon BD, et al. Insights into neuroepigenetics through human histone deacetylase PET imaging. Sci Transl Med. 2016;8(351):351ra106.","journal-title":"Sci Transl Med"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1038\/s41467-022-30653-5","article-title":"[(11)C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer's disease","volume":"13","author":"Pascoal TA","year":"2022","unstructured":"Pascoal TA, Chamoun M, Lax E, Wey HY, Shin M, Ng KP, et al. [(11)C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer's disease. Nat Commun. 2022;13(1):4171.","journal-title":"Nat Commun"},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mds.10459","article-title":"Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders","volume":"18","author":"Litvan I","year":"2003","unstructured":"Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18(5):467\u201386.","journal-title":"Mov Disord"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson's disease","volume":"22","author":"Emre M","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689\u2013707; quiz 837.","journal-title":"Mov Disord"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith IG","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"17","key":"ref44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies","volume":"94","author":"McKeith IG","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743\u201355.","journal-title":"Neurology"},{"issue":"15","key":"ref45","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz CG","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370.","journal-title":"Mov Disord"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn MM","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342.","journal-title":"Neurology"},{"issue":"4","key":"ref47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine ZS","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","article-title":"An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest","volume":"31","author":"Desikan RS","year":"2006","unstructured":"Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968\u201380.","journal-title":"Neuroimage"},{"issue":"3","key":"ref49","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0896-6273(02)00569-X","article-title":"Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain","volume":"33","author":"Fischl B","year":"2002","unstructured":"Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341\u201355.","journal-title":"Neuron"},{"issue":"1","key":"ref50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cercor\/bhg087","article-title":"Automatically parcellating the human cerebral cortex","volume":"14","author":"Fischl B","year":"2004","unstructured":"Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14(1):11\u201322.","journal-title":"Cereb Cortex"},{"issue":"Suppl 1","key":"ref51","doi-asserted-by":"crossref","first-page":"A57","DOI":"10.1186\/2197-7364-1-S1-A57","article-title":"Masamune: a tool for automatic dynamic PET data processing, image reconstruction and integrated PET\/MRI data analysis","volume":"1","author":"Chonde DB","year":"2014","unstructured":"Chonde DB, Izquierdo-Garcia D, Chen K, Bowen SL, Catana C. Masamune: a tool for automatic dynamic PET data processing, image reconstruction and integrated PET\/MRI data analysis. EJNMMI Phys. 2014;1(Suppl 1):A57.","journal-title":"EJNMMI Phys"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.neuroimage.2016.02.042","article-title":"Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging","volume":"132","author":"Greve DN","year":"2016","unstructured":"Greve DN, Salat DH, Bowen SL, Izquierdo-Garcia D, Schultz AP, Catana C, et al. Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging. Neuroimage. 2016;132:334\u201343.","journal-title":"Neuroimage"},{"issue":"11","key":"ref53","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1001\/jamaneurol.2013.3579","article-title":"Incidence of dementia with Lewy bodies and Parkinson disease dementia","volume":"70","author":"Savica R","year":"2013","unstructured":"Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013;70(11):1396\u2013402.","journal-title":"JAMA Neurol"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman BT","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8(1):1\u201313.","journal-title":"Alzheimers Dement"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.nicl.2015.06.001","article-title":"Putamen-midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases","volume":"8","author":"Rieckmann A","year":"2015","unstructured":"Rieckmann A, Gomperts SN, Johnson KA, Growdon JH, Van Dijk KR. Putamen-midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases. Neuroimage Clin. 2015;8:554\u20139.","journal-title":"Neuroimage Clin"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00702-023-02688-5","article-title":"Bradykinesia and rigidity modulated by functional connectivity between the primary motor cortex and globus pallidus in Parkinson's disease","volume":"130","author":"Kinugawa K","year":"2023","unstructured":"Kinugawa K, Mano T, Fujimura S, Takatani T, Miyasaka T, Sugie K. Bradykinesia and rigidity modulated by functional connectivity between the primary motor cortex and globus pallidus in Parkinson's disease. J Neural Transm (Vienna). 2023;130(12):1537\u201345.","journal-title":"J Neural Transm (Vienna)"},{"issue":"9","key":"ref57","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/hbm.21118","article-title":"Functional connectivity of cortical motor areas in the resting state in Parkinson's disease","volume":"32","author":"Wu T","year":"2011","unstructured":"Wu T, Long X, Wang L, Hallett M, Zang Y, Li K, et al. Functional connectivity of cortical motor areas in the resting state in Parkinson's disease. Hum Brain Mapp. 2011;32(9):1443\u201357.","journal-title":"Hum Brain Mapp"},{"issue":"1","key":"ref58","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1038\/s41467-019-11031-0","article-title":"Neuroepigenetic signatures of age and sex in the living human brain","volume":"10","author":"Gilbert TM","year":"2019","unstructured":"Gilbert TM, Zurcher NR, Catanese MC, Tseng CJ, Di Biase MA, Lyall AE, et al. Neuroepigenetic signatures of age and sex in the living human brain. Nat Commun. 2019;10(1):2945.","journal-title":"Nat Commun"},{"key":"ref59","article-title":"Investigating neuroepigenetic alterations in chronic low back pain with positron emission tomography","author":"Yoo CH","year":"2024","unstructured":"Yoo CH, Rani N, Shen S, Loggia ML, Gaynor K, Moore KE, et al. Investigating neuroepigenetic alterations in chronic low back pain with positron emission tomography. Pain. 2024.","journal-title":"Pain"},{"issue":"7","key":"ref60","doi-asserted-by":"crossref","first-page":"110159","DOI":"10.1016\/j.isci.2024.110159","article-title":"Toward AI-driven neuroepigenetic imaging biomarker for alcohol use disorder: A proof-of-concept study","volume":"27","author":"Dagnew TM","year":"2024","unstructured":"Dagnew TM, Tseng CJ, Yoo CH, Makary MM, Goodheart AE, Striar R, et al. Toward AI-driven neuroepigenetic imaging biomarker for alcohol use disorder: A proof-of-concept study. iScience. 2024;27(7):110159.","journal-title":"iScience"},{"issue":"4","key":"ref61","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/jnnp-2017-316844","article-title":"Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis","volume":"89","author":"Rizzo G","year":"2018","unstructured":"Rizzo G, Arcuti S, Copetti M, Alessandria M, Savica R, Fontana A, et al. Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89(4):358\u201366.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6647341\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6647341\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:02:59Z","timestamp":1769443379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6647341\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":61,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6647341\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s13148-026-02054-8","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,8,11]]},"subtype":"preprint"}}